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FUNCTIONAL ASSESSMENT OF THE RAS/MAPK PATHWAY 
ELIZABETH GAGEN 
ABSTRACT 
 Rasopathies are a heterogeneous group of disorders that are due to dominant, 
gain-of-function mutations in genes in the RAS/MAPK pathway.  The RAS/MAPK 
pathway is involved in regulating cell growth, differentiation, and apoptosis.  There is 
marked clinical variation in clinical phenotypes among different rasopathies despite 
activation of the RAS/MAPK pathway, suggesting that there may be additional 
biochemical variables depending on the gene mutated.  In this thesis, the activation of the 
end effectors of the RAS/MAPK pathway, MAPK and MEK, were analyzed using 
Western blots and flow cytometry in NF1, RIT1, and PTPN11 mutated fibroblasts and 
lymphoblasts.  Although the mutated cell lines were expected to have higher levels of 
activation due to upregulation of the RAS/MAPK pathway, they were found to have 
decreased activation compared to the control cells.  A suggested reason for these results 
is that negative feedback loops may decrease the level of activation in the pathway by 
having activated P-MAPK and P-MEK inhibit previous proteins in the pathway. 
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INTRODUCTION 
 
The RAS/MAPK pathway (figure 1) is a highly conserved signaling pathway that 
regulates gene expression for cell growth and differentiation using mitogen activated 
protein kinases (MAPKs).  The pathway is involved in the pathophysiology of different 
genetic disorders underscoring its biological importance for cell cycle regulation and cell 
differentiation.  Because of its impact on cell growth, it commonly has a role in cancer 
and has been consequently well studied (Aoki, Niihori, Narumi, Kure, & Matsubara, 
2008).  It is estimated that approximately one third of all human cancers involve 
dysregulation of the RAS/MAPK pathway.  Twenty percent of tumors carry a driver 
mutation in the RAS (rat sarcoma) gene (Dhillon, Hagan, Rath, & Kolch, 2007; 
Downward, 2003; Tidyman & Rauen, 2009).  Germline mutations in the RAS/MAPK 
pathway lead to a heterogeneous group of developmental disorders termed rasopathies 
(Tidyman & Rauen, 2009). 
 
The RAS/MAPK Pathway 
RAS proteins are a family of GTPases that are involved in several signaling 
pathways that relate to cell growth.  Their downstream effectors include phosphoinositide 
3-kinases (PI3K), RAL guanine nucleotide dissociation stimulators (RALGDS), 
phospholipase Ce (PLCe), and rapidly accelerated fibrosarcoma (RAF) (Downward, 2003; 
Zebisch & Troppmair, 2006).  RAF initiates the MAPK pathway, which leads to the 
activation of extracellular signal-regulated kinase (ERK), ERK1/2, the final MAPK in the 
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pathway.  ERK1/2 has over 200 substrates in the nucleus, cytoplasm, and within other 
organelles, with about half being in the nucleus (Plotnikov, Zehorai, Procaccia, & Seger, 
2011). 
 
 
Figure 1: The RAS/MAPK Pathway.  The RAS/MAPK pathway initiates signaling at 
the plasma membrane.  Following activation, the RTK activates RAS.  RAS initiates the 
signaling cascade that ends with the phosphorylation and activation of MAPK (ERK1/2).  
P-MAPK can then stimulate transcription in the nucleus as well as target cytosolic 
substrates. 
 
RAS proteins are GTPases that exchange guanosine diphosphate (GDP) in its 
inactive form for guanosine triphosphate (GTP) to become active.  The pathway is 
initiated when receptor tyrosine kinases (RTK) are activated by the binding of an 
extracellular growth factor (Friday & Adjei, 2008).  The RTK phosphorylates itself and 
interacts with adaptor protein growth factor receptor-bound protein 2 (GRB2), which is 
bound to son-of-sevenless (SOS1/2) and recruited to the plasma membrane (Tidyman & 
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Rauen, 2009).  SOS1/2 are guanosine nucleotide exchange factors (GEFs) that increase 
the rate at which RAS exchanges GDP for GTP (Tidyman & Rauen, 2016). This initiates 
a signaling cascade where RAS activates RAF, which then activates mitogen-activated 
protein kinase kinase 1/2 (MEK1/2), and then ERK1/2 through phosphorylation 
(Tidyman & Rauen, 2009).  The active phosphorylated ERK1/2 (MAPK) can then move 
into the nucleus and act as a transcription factor, regulating the transcription of genes 
needed for cell growth and proliferation (Tidyman & Rauen, 2016).  It also has targets in 
the mitochondria, Golgi, and endosome, as well as cytosolic targets that help regulate 
mitosis and apoptosis (Wainstein & Seger, 2016; Wortzel & Seger, 2011; Yao & Seger, 
2009).  Germline mutations in genes in or affecting the RAS/MAPK pathway lead to 
upregulation of the pathway resulting in rasopathies (Tidyman & Rauen, 2016).  
 
 
Figure 2: Effects of ERK1/2.  Phosphorylated ERK1/2 has targets in the cytosol, 
nucleus, and other organelles including the mitochondria, Golgi, and endosome.  These 
targets regulate components of cell differentiation, mitosis, apoptosis, and cell 
senescence.  
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RAS 
RAS proteins are small GTPases which exchange bound GDP for GTP to become 
activated (Simanshu, Nissley, & McCormick, 2017).  The cycling of GDP to GTP is 
assisted by GEFs, and reversed by GTPase activating proteins (GAPs) (Santarpia, 
Lippman, & El-Naggar, 2012).  Somatic mutations in RAS appear in 20% of malignant 
cancers (Dhillon et al., 2007; Downward, 2003; Tidyman & Rauen, 2009).  Mutations in 
different RAS proteins can result in different rasopathies by interfering with the GTPase 
function of RAS, including in the Harvey rat sarcoma viral oncogene homologue (HRAS), 
Kirsten rat sarcoma viral oncogene homologue (KRAS), RAS viral oncogene homologue 
(RRAS), and neuroblastoma RAS viral oncogene homologue (NRAS) genes (Tidyman & 
Rauen, 2016).  Gain-of-function mutations in HRAS lead to Costello Syndrome (CS), 
while mutations in KRAS cause Noonan syndrome (NS) and Cardio-Facio-Cutaneous 
syndrome (CFC) (Aoki et al., 2008).  NRAS and RRAS mutations have been found in 
some individuals with a NS phenotype (Tidyman & Rauen, 2016).  There is clinical 
overlap between the different types of rasopathies underscoring the close functional 
relationship of the underlying proteins. 
 
RIT1 
RIT1 is a gene that encodes the protein RIC-like protein without CAAX motif 1 
(RIT1), a member of the RAS subfamily. It is a GTPase that has over 50% sequence 
identity with other RAS proteins (Aoki et al., 2013).  Gain-of-function mutations in RIT1 
lead to increased ERK1/2 activation, as well as increased activation of the transcription 
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factor ELK1 by ERK2 (Koenighofer et al., 2016).  Heterozygous mutations in the RIT1 
gene have been found in patients with NS (Bertola et al., 2014). 
 
NF1 
 NF1 is a tumor suppressor gene that encodes neurofibromin, a RasGAP and a 
negative regulator of the RAS/MAPK pathway.  It binds to active GTP-bound RAS and 
enhances its GTPase activity, making RAS inactive (Tidyman & Rauen, 2016).  
Interaction with SPRED1 localizes neurofibromin to the membrane with RAS (Ratner & 
Miller, 2015).  Loss of function mutations in NF1 activates the RAS/MAPK pathway and 
causes neurofibromatosis type 1 (NF1) (Ratner & Miller, 2015). 
 
SOS1/2 
 SOS1/2 are RasGEFs.  Heterozygous autosomal dominant mutations in SOS1/2 
have been identified in patients with NS.  Gain of function mutations increase RAS 
activation by preventing SOS1/2 from autoinhibiting itself (Tidyman & Rauen, 2016).  
This occurs because missense mutations occur in the Dbl homology (DH) domain which 
contributes to stabilization of the autoinhibited conformation of SOS1/2 (Tartaglia et al., 
2007; Yamamoto et al., 2015).    
 
PTPN11 
 Protein Tyrosine Phosphatase Non-receptor type 11 (PTPN11) encodes the 
protein tyrosine phosphatase SHP2.  SHP2 contains a catalytic PTP domain which is 
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autoinhibited by one of its own two SH2 domains when inactive (Tartaglia et al., 2001).  
SHP2 binds to growth factor receptors, which is necessary for activation (Kontaridis, 
Swanson, David, Barford, & Neel, 2006).  Gain of function mutations in PTPN11 prevent 
autoinhibition and cause NS (Tidyman & Rauen, 2016).  Dominant PTPN11 mutations 
are the most common cause of NS and are responsible for more than 50% of cases 
(Bertola et al., 2014; Chen et al., 2014).  Dominant negative mutations have also been 
found to cause NS with multiple lentigines, also known as LEOPARD syndrome 
(Kontaridis et al., 2006). 
 
RAF 
 The RAF family of genes encode serine/threonine kinases which include BRAF 
and RAF1.  They form a heterodimer are directly downstream of RAS and are activated 
through phosphorylation by RAS (Freeman, Ritt, & Morrison, 2013).  BRAF encodes v-
Raf murine sarcoma viral oncogene homolog B (BRAF) which phosphorylates MEK1/2.  
Activating mutations in BRAF lead to CFC (Niihori et al., 2006).  RAF1 encodes v-raf-1 
murine leukemia viral oncogene homologue 1 (CRAF/RAF1).  RAF1 also 
phosphorylates MEK1/2, and gain of function mutations lead to Noonan Syndrome and 
Noonan Syndrome with multiple lentigines (Pandit et al., 2007). 
 
MEK1/2 
 MEK1/2 are threonine/tyrosine kinases which are encoded by MAP2K1/MAP2K2 
(Tidyman & Rauen, 2016).  They phosphorylate and activate ERK1/2, their only 
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substrate (Plotnikov et al., 2011).  Gain of function mutations in MEK1/2 cause CFC 
(Rodriguez-Viciana et al., 2006).  Deletion of MEK2 has been found to cause a 
phenotype similar to CFC, although the RAS/MAPK pathway is downregulated instead 
of upregulated (Nowaczyk et al., 2014). 
 
Rasopathies  
Rasopathies are a group of developmental disorders that are caused by germline 
mutations in genes within or affecting the RAS/MAPK pathway (Koenighofer et al., 
2016).  Over 1 in 1000 people are affected (Jindal et al., 2017; Tidyman & Rauen, 2016).  
Diagnoses are historically based on clinical phenotype but since the identification of 
underlying disease genes, confirmation by molecular genetic testing is standard of care.  
However, about 20% of patients with a rasopathy phenotype do not have an identifiable 
mutation in a known rasopathy gene (Koenighofer et al., 2016).  Disease-associated 
mutations disrupt the regulation of and activate the RAS/MAPK pathway, resulting in 
diverse phenotypes ranging from Neurofibromatosis type 1 to Noonan Syndrome.  There 
is also a wide range in the severity of the symptoms, even within the same disorder and 
with mutations in the same gene (Jindal et al., 2017).  This could be due to the presence 
of other genes or epigenetic factors differing between individuals.  Although various 
mutations cause rasopathies, they all lead to increased phosphorylation and activation of 
the pathway, resulting in overlapping phenotypes (Pevec, Rozman, Gorsek, & Kunej, 
2016).  The clinical phenotype is highly variable but may include abnormalities in the 
cardiovascular system, musculoskeletal system, and neurological system (Aoki, Niihori, 
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Inoue, & Matsubara, 2016).  Craniofacial dysmorphology, intellectual disability, and 
short stature are among the many symptoms described (Pevec et al., 2016).  Some 
rasopathies can cause an increased risk of developing cancers, as some cancers also 
involve upregulation of the RAS/MAPK pathway (Kratz et al., 2015; Rauen, 2013).  
Despite activating the same pathway, the varying phenotypes indicate that there may be 
differences in how these different mutations affect the pathway.  A brief summary of the 
most common rasopathies are given below. 
 
Neurofibromatosis type 1 
 NF1 is a condition that affects approximately 1 in 3000 individuals (Ratner & 
Miller, 2015; Rauen, 2013).  It was the first syndrome identified to be caused by a 
germline mutation in the RAS/MAPK pathway (Rauen, 2013).  It is caused by loss of 
function mutations in NF1, a negative regulator of the pathway (Tidyman & Rauen, 
2016).  Clinical diagnosis of patients with NF1 is based on symptoms including café-au-
lait spots, cutaneous neurofibromas, iris Lisch nodules, intertriginous freckling, optic 
pathway gliomas, or a first degree relative with NF1 (Ratner & Miller, 2015; Rauen, 
2013; Tidyman & Rauen, 2016). Since NF1 is a tumor suppressor gene, individuals with 
NF1 have an increased chance of developing cancers (Rauen, 2013). 
 
Noonan Syndrome 
 Noonan syndrome (NS) is an autosomal dominant disorder that occurs in 1 in 
1,000 to 2,500 individuals (Aoki et al., 2013; Romano et al., 2010).  It is characterized by 
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short stature, distinctive facial features such as widely spaced eyes with epicanthal folds, 
webbed neck, and congenital heart defects, such as pulmonary valve stenosis (Allanson, 
2016; Romano et al., 2010).  There are different genes that have been found to have 
germline mutations in individuals with NS, with the most common being PTPN11 in 
about 50% of NS cases (Aoki et al., 2013).   
 
 
Figure 3. Patient with Noonan Syndrome.  A patient with Noonan Syndrome at 10 
days, 6 months, and 2 years old, showing the characteristic facial features (taken from 
Romano et al., 2010). 
 
LEOPARD Syndrome 
 LEOPARD syndrome (multiple lentigines, electrocardiographic-conduction 
abnormalities, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retardation 
of growth, and sensorineural deafness)/Noonan syndrome with multiple lentigines is 
phenotypically similar to NS, however also includes café-au-lait spots (Digilio et al., 
2002).  It is caused by mutations in PTPN11 and RAF1, which are genes that are also 
mutated in NS (Lee, Ki, & Lee, 2007; Tidyman & Rauen, 2016).   
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Legius Syndrome 
 Legius syndrome has the phenotype of mild NF1 (Brems et al., 2012).  It is 
caused by mutations in sprouty-related EVH1 domain containing 1 (SPRED1), a negative 
regulator of the RAS/MAPK pathway (Tidyman & Rauen, 2016).  Individuals with 
Legius syndrome can have café-au-lait spots and intertriginous freckling, but do not have 
the tumors normally associated with NF1 (Brems et al., 2012). 
 
 Costello Syndrome 
 Costello syndrome (CS) is a less common rasopathy that phenotypically overlaps 
with NS resulting in dysmorphic facial features and heart defects such as pulmonary 
valve stenosis and hypertrophic cardiomyopathy (Bezniakow, Gos, & Obersztyn, 2014; 
Gelb & Tartaglia, 2006).  Benign tumors called papillomas often appear around the 
mouth during childhood (Bezniakow et al., 2014).  It is caused only by mutations in 
HRAS, a GTPase (Gripp & Lin, 2012; Tidyman & Rauen, 2016) 
 
Cardio-facio-cutaneous Syndrome 
 Cardio-facio-cutaneous syndrome (CFC) has a lot of phenotypic overlap with NS 
and CS but has a more severe effect (Bezniakow et al., 2014).  It is characterized by 
similar heart defects, dysmorphic facial features, and developmental delay (Rodriguez-
Viciana et al., 2006).  Unlike NS, it is often associated with neurodevelopmental 
disorders such as psychomotor developmental delay, frontal lobe hypoplasia, and 
hydrocephalus (Bezniakow et al., 2014).  
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Rasopathy Genes Incidence Phenotype 
Noonan Syndrome PTPN11 
SOS1/2 
RAF1 
KRAS 
RRAS 
NRAS 
RIT1 
1 in 1,000 to 1 in 
2,500 
Dysmorphic facial features 
such as epicanthal folds, 
wide spaced eyes, webbed 
neck; congenital heart 
defects such as pulmonary 
valve stenosis; short stature 
Costello Syndrome HRAS Estimated 1 in 
1,290,000 
Dysmorphic facial features, 
heart defects such as 
pulmonary valve stenosis and 
hypertrophic 
cardiomyopathy; papillomas; 
curly hair 
Neurofibromatosis 
type 1 
NF1 1 in 3,000 Café-au-lait spots, cutaneous 
neurofibromas, iris Lisch 
nodules, intertriginous 
freckling, optic pathway 
glioma  
Cardio-Facio-
Cutaneous Syndrome 
BRAF 
KRAS 
Estimated 1 in 
810,000 in Japan 
Dysmorphic facial features, 
failure to thrive, short 
stature, neurodevelopmental 
delay 
Legius Syndrome SPRED1 Unknown Café-au-lait spots, 
intertriginous freckling 
LEOPARD  PTPN11 
RAF1 
Unknown Similar to NS but with 
multiple lentigines, café-au-
lait spots 
 
Table 1. Rasopathies.  Different rasopathies and the genes and phenotypes associated 
with them. 
 
Aims and objectives  
There is marked variability of clinical symptoms and their severity between 
different rasopathies, which points towards a more specific role of each gene within the 
context of the RAS/MAPK pathway.  The hypothesis of this thesis is that there are indeed 
gene, protein, and/or variant specific effects on pathway upregulation.  Specific Aim 1: 
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To establish and validate a Western blot protocol on control and patient fibroblast and 
lymphoblast cell lines with the intent to detect and semiquantify levels of MAPK, 
MEK1/2 (MEK), phosphorylated MAPK (P-MAPK), and phosphorylated MEK (P-
MEK).  Specific Aim 2: To establish and validate a flow cytometry protocol on control 
and patient fibroblast and lymphoblast cell lines with the intent to detect and quantify 
levels of MAPK, MEK, P-MAPK, and P-MEK.  This approach would potentially provide 
an opportunity for developing a relatively simple diagnostic test for rasopathies.
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METHODS 
Cell culture 
Normal control and NS lymphoblast cell lines (PTPN11 c.1403>T (p.T468M) 
Exon 12), and normal control, RIT1 (c.270G>C (p.Met90Ile)) and 4 NF1 fibroblasts cell 
lines (NF1 #3 is c.1183insT (NM_001042492.2) Exon 10) from the Coriell Institute for 
Medical Research were used for the experiments.  The cells were cultured in sterile 
growth medium (DMEM/F12 for fibroblasts, RPMI-1640 for lymphoblasts, 15% fetal 
bovine serum, 1% penicillin-streptomycin-glutamine) at 37°C and 5% CO2.  Fibroblasts 
were counted using the Countess II Automatic Cell Counter (Thermo Fisher Scientific, 
Waltham, MA) and 500,000 cells were plated into 10 cm plates until they reached 70-
80% confluency.  Lymphoblasts were counted and lysates were prepared with 7x106 cells 
per lysate. 
 
Western Blot  
Cell lysates were prepared by suspending the harvested cells in a kinase lysis 
buffer containing protease and phosphatase inhibitors.  After sonication on ice for five 
seconds five times on level 3 using a sonic dismembrator instrument (level 3, Model 100, 
Thermo Fisher Scientific, Waltham, MA), the cells were spun at 14,000 rpm for 10 
minutes at room temperature and the supernatant kept at -80 °C.  Protein concentration 
was measured using the Pierce bicinchoninic acid (BCA) protein assay kit (Thermo 
Fisher Scientific, Waltham, MA) and normalized prior to loading equal amounts of 
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protein for each sample.  35 - 45 ug of protein were used for each sample.  The protein 
lysates were mixed with 4X lithium dodecyl sulfate (LDS) loading dye, 10X reducing 
agent, and dH2O, heated for 5 minutes at 98°C, and centrifuged at 14,000 rpm for 10 
minutes at room temperature.  Samples were run on 10% Bis-Tris gels (Invitrogen, 
Carlsbad, CA) for 40 minutes at 200 volts and then transferred to a nitrocellulose 
membrane (Invitrogen, Carlsbad, CA) using the iBlot dry blotting system on the preset 
protocol #0 (Thermo Fisher Scientific, Waltham, MA).  Non-specific binding was 
blocked with 5% bovine serum albumin (BSA) in 10% Tween-20 in tris-buffered saline-
Tween (TBS-T) for 1 hour.  The membranes were washed in TBS-T and incubated in the 
primary antibodies, diluted in 5% BSA overnight at 4 °C.  They were then washed and 
incubated in the secondary antibody, horseradish peroxidase (HRP) conjugated anti-
rabbit IgG antibody (1:2000; Cell Signaling, Danvers, MA) diluted in 5% BSA, for 1 
hour.  The blots were developed in an enhanced chemiluminescent detection reagent 
(ECL) (GE Healthcare, Chicago, IL) for 5 minutes and exposed in a chemiluminescence 
imager (ChemiDoc XRS+ System, Bio-Rad, Hercules, CA).  The primary antibodies 
were MAPK (1:1000; Cell Signaling, Danvers, MA), MEK (1:1000; Cell Signaling, 
Danvers, MA), P-MAPK (1:2000; Cell Signaling, Danvers, MA), and P-MEK (1:1000; 
Cell Signaling, Danvers, MA).  After imaging, the blots were washed in TBS-T and 
blocked again for 1 hour in 5% BSA before incubating in HRP conjugated 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1:1000; Cell Signaling, Danvers, 
MA) for 1 hour as a loading control.  They were redeveloped in ECL and imaged again. 
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Western Blot quantification 
GAPDH is an enzyme that is used in glycolysis and is highly expressed, making it 
a good loading control (Seidler, 2013).  It was used to quantify the protein expression for 
each antibody in comparison with each other as well as to account for differences due to 
unequal loading despite normalization.  The program Fiji (Schindelin et al., 2012) was 
used to find the percent density of each band.  After choosing one normal control to 
compare the others against, the percentages could then be used to calculate the relative 
densities of each band of GAPDH.  The percent densities of each sample band were 
divided by the relative density of the respective GAPDH band to find the adjusted 
densities.  The adjusted densities were calculated for each band separately as well as for 
the total adjusted density for each band within one lane.  
 
Flow cytometry  
 Lymphoblasts were counted and measured so that there were 2x106 cells per 
sample.  Noonan and normal control cells were split into 2 groups, treated and untreated 
with phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich, St. Louis, MO) to induce 
phosphorylation.  PMA treatment was at 400nM in phosphate-buffered saline (PBS) for 
15 minutes at 37°C.  Cells were then stained with the fluorescent stain 4’,6-diamidino-2-
phenylindole (DAPI) at 1uL/1mL in PBS for 10 minutes at room temperature, and then 
incubated in BD Pharmigen Stain buffer (BD Biosciences, Franklin Lakes, NJ) at room 
temperature for 10 minutes.  They were fixed in BD Phosflow Lyse/Fix Buffer (BD 
Biosciences, Franklin Lakes, NJ) for 10 minutes at 37 °C and washed with Stain buffer.  
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To permeabilize the cells, they were incubated at room temperature for 10 minutes in a 
saponin permability buffer diluted in 1% BSA in PBS.  The cells were washed in Stain 
buffer, recounted, and then resuspended in stain buffer at 1x106 cells/100 uL.  Antibodies 
were added and the samples were incubated on ice in the dark for 30 minutes.  Next, the 
cells were washed and resuspended in Stain buffer at 1x106 cells/100 uL.  The antibodies 
used were PE conjugated MEK1/2 rabbit mAb (1:50; Cell Signaling, Danvers, MA), 
Alexa Fluor 647 conjugated mouse anti-MEK1 (pS218)/MEK2 (pS222) (5ul/1x106 cells; 
BD Biosciences, Franklin Lakes, NJ), Alexa Fluor 647 conjugated p44/42 MAPK 
(Erk1/2) rabbit mAb (1:50; Cell Signaling, Danvers, MA), and Alexa Fluor 488 
conjugated Phospho-p38 MAPK (Thr180/Tyr182) mouse mAb (1:50; Cell Signaling, 
Danvers, MA).  The samples were counted using the LSRFortessa cell analyzer (BD 
Sciences, Franklin Lakes, NJ). 
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RESULTS 
Western Blots 
Fibroblasts 
 Western blots were done using normal control, RIT1, and NF1 mutated fibroblasts 
to measure levels of protein expression for MAPK, MEK, P-MAPK, and P-MEK.  
GAPDH was used as a loading control.    
     
      
Figure 4. Protein expression in fibroblasts.  A) MAPK, B) MEK, C) P-MAPK, and D) 
P-MEK were used as primary antibodies on 3 different control cell lines, 4 different NF1 
cell lines (1-4 from left to right), and a RIT1 cell line.  GAPDH was used as a loading 
control. 
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A) 
 MAPK P-MAPK MEK P-MEK 
RIT1 39.93 5.98 21.27 15.78 
NF1 1 22.71 4.47 15.27 14.36 
NF1 2 25.97 10.07 17.57 17.59 
NF1 3 26.28 13.97 30.27 15.71 
NF1 4 42.58 13.55 80.09 17.19 
Control 1 12.96 41.65 19.97 29.75 
Control 2 18.60 37.88 21.59 35.48 
Control 3 16.03 19.01 12.87 42.69 
 
B) 
RIT1 MAPK P-MAPK MEK P-MEK 
Band 1 20.56 3.34 21.27 10.26 
Band 2 19.45 2.67  4.91 
NF1 1 MAPK P-MAPK MEK P-MEK 
Band 1 11.29 1.92 15.27 10.52 
Band 2 11.49 2.56  3.89 
NF1 2 MAPK P-MAPK MEK P-MEK 
Band 1 15.24 2.69 17.57 9.58 
Band 2 10.76 6.43  7.64 
NF1 3 MAPK P-MAPK MEK P-MEK 
Band 1 13.61 6.06 30.27 9.70 
Band 2 12.67 7.48  4.93 
NF1 4 MAPK P-MAPK MEK P-MEK 
Band 1 22.96 2.87 80.09 11.30 
Band 2 19.58 10.81  6.29 
Control 1 MAPK P-MAPK MEK P-MEK 
Band 1 5.58 16.48 19.97 22.27 
Band 2 7.29 25.53  8.26 
Control 2 MAPK P-MAPK MEK P-MEK 
Band 1 7.98 12.18 21.59 21.53 
Band 2 10.59 26.02  16.37 
Control 3 MAPK P-MAPK MEK P-MEK 
Band 1 6.05 6.00 12.87 20.13 
Band 2 10.22 13.55  19.68 
 
Table 2. Fibroblast Western blot quantification.  The adjusted densities of the Western 
blot bands from Figure 2 based on the GAPDH loading control.  A) The adjusted density 
of the total protein expression for each protein. B) The adjusted density of each band. 
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This Western blot (figure 4) shows that there was increased phosphorylation of 
MAPK and MEK in the control fibroblasts compared to the RIT1 or NF1 mutated 
fibroblasts. The adjusted densities of P-MAPK for the control samples range from 19.51 
to 41.65 with an average of 32.84, while the adjusted densities of the NF1 samples range 
from 4.47 to 13.97 with an average of 10.52, and the RIT1 sample is only 5.98.  The 
densities for the control samples are significantly larger (p = 0.0059).  For P-MEK, the 
densities of the normal control samples range from 29.75 to 42.69 with an average of 
35.97, versus 14.36 to 17.59 with an average of 16.21 for NF1 and 15.78 for RIT1 (p = 
0.0004).  This is contrary to what was expected since gain-of-function mutations in NF1 
and RIT1 result in upregulation of the RAS/MAPK pathway.  The lower levels of P-
MAPK in the mutated cells cannot be attributed to less available MAPK as the mutated 
cells have higher levels of unphosphorylated MAPK.  Although the control samples have 
higher levels of P-MAPK, they have lower levels of MAPK compared to the RIT1 and 
NF1 samples.  The levels of unphosphorylated MEK are relatively equal across the 
different samples with the exception of the fourth NF1 sample which has an adjusted 
density of 80.09, however the patient samples do not have a significantly higher level of 
MEK in comparison to the control samples and therefore the differences in P-MEK 
cannot be attributed to differences in total MEK. 
There is also no noticeable difference in the level of activation between the RIT1 
and NF1 samples.  Although there is only 1 RIT1 sample, the levels of P-MAPK and P-
MEK fall within the range of levels for the 4 NF1 samples.   
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Lymphoblasts 
  Western blots were done on normal control (C) and Noonan (NS) untreated 
lymphoblasts to measure protein expression of MAPK, P-MAPK, MEK, and P-MEK.  
GAPDH was used as a loading control.   
 
Figure 5: Protein expression in lymphoblasts.  Lysates from normal control (C) and 
Noonan Syndrome (NS) lymphoblasts were used to measure levels of MAPK, P-MAPK, 
MEK, and P-MEK protein.  GAPDH (1:1000) was used as a loading control. 
 
A) 
 MAPK P-MAPK MEK P-MEK 
Control 10.66 4.27 15.66 7.13 
NS 9.18 1.49 15.89 5.00 
 
B) 
Control MAPK P-MAPK MEK P-MEK 
Band 1 3.38 0.98 14.23 5.94 
Band 2 4.29 3.29 1.43 1.20 
Band 3 2.99    
NS MAPK P-MAPK MEK P-MEK 
Band 1 2.61 1.92 14.63 3.43 
Band 2 4.09 1.26 1.27 1.56 
Band 3 2.48    
 
Table 3. Lymphoblast Western blot quantification.  The adjusted densities of the 
Western blot in Figure 3 using GAPDH as a loading control. A) The adjusted density of 
the total antibody expression for each antibody. B) The adjusted density of each band. 
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Table 3 shows that a greater amount of MEK and MAPK is phosphorylated in the 
control lymphoblasts than in the NS lymphoblasts.  As with the fibroblasts, this 
difference cannot be attributed to higher total MAPK and MEK levels in the control cells.  
The adjusted density of unphosphorylated MAPK in the control cells is 10.66 which is 
only slightly higher than the NS cells at 9.18, and the adjusted densities for 
unphosphorylated MEK are around the same for both control and NS cells at 15.66 and 
15.89 respectively.  Similar to the fibroblasts, the control cells were not expected to have 
higher levels of phosphorylation.  Since in NS the RAS/MAPK pathway is upregulated, 
we would expect to see more P-MAPK and P-MEK signal in the NS lymphoblasts than 
the control.   
 
Flow Cytometry 
 
 NS lymphoblasts and normal control lymphoblasts were prepared.  Lymphoblasts 
were stained with DAPI and separated into 2 groups and either treated with PMA to 
induce phosphorylation or left untreated.  All of the cells were stained with antibodies for 
MAPK, MEK, P-MAPK, and P-MEK.   
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Figure 6. Flow cytometry cell counts of total MAPK and MEK.  Normal control (red) 
and NS lymphoblasts (blue) were stained with antibodies for A) MAPK and B) MEK. 
 
 The proportion of cells stained with unphosphorylated MAPK and MEK was 
higher in the NS lymphoblasts than in the normal control lymphoblasts, although there 
was low signal for MAPK.  To increase the signal, cells were treated with PMA to induce 
phosphorylation. 
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Figure 7. Flow cytometry cell counts of P-MAPK and P-MEK.  Normal control and 
NS lymphoblasts treated with PMA were stained with antibodies for A) P-MAPK and B) 
P-MEK.  Normal control and NS lymphoblasts that were untreated were also stained with 
antibodies for C) P-MAPK and D) P-MEK. 
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Figure 5 shows that cells that were treated with PMA had higher levels of 
phosphorylation as expected.  Despite having higher levels of unphosphorylated MAPK 
and MEK, normal control lymphoblasts also had higher levels of P-MAPK and P-MEK 
than the NS lymphoblasts, which is consistent with the data from the Western blots.  
While the treated control lymphoblasts had about 1.5 times as much P-MEK than NS 
lymphoblasts, they had about 11.7 times as much P-MAPK.  The cells that were 
untreated had lower levels of phosphorylation overall, although the normal control 
lymphoblasts had about 3 times as much P-MEK as the NS cells and an almost the same 
but still greater amount of P-MAPK.  
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DISCUSSION 
 
 The RAS/MAPK pathway has an important biological role in regulating the cell 
cycle and apoptosis.  When the pathway is activated, cell growth and differentiation are 
promoted.  In this thesis, the activation of MAPK and MEK in patient cell lines was 
measured to determine if different mutations result in different levels of upregulation 
depending on the proximity of the gene to the end effectors of the RAS/MAPK pathway.  
An established Western blot protocol was adapted and validated to analyze and 
semiquantify total and activated levels of MAPK and MEK in normal control, NF1, and 
RIT1 fibroblasts.  A flow cytometry protocol was developed and validated to analyze and 
quantify total and activated levels of MAPK and MEK in normal control and NS 
lymphoblasts.    
 Cells with mutations in proteins in the RAS/MAPK pathway were expected to 
have increased activation of the pathway, resulting in higher than normal levels of P-
MAPK and P-MEK.  Instead, the Western blots showed higher levels of P-MAPK and P-
MEK in the control fibroblasts than in RIT1, NF1, and NS mutated fibroblasts and 
lymphoblasts.  The flow cytometry data also showed higher levels of P-MAPK and P-
MEK in control lymphoblasts than in NS lymphoblasts which is consistent with the 
Western blot data.  These results may be explained by negative feedback loops within the 
RAS/MAPK pathway.  Negative feedback loops are a type of regulation where a process 
is inhibited by its own product.  This helps keep systems in equilibrium.  Negative 
feedback loops would cause the RAS/MAPK pathway to be suppressed, leading to 
decreased activation of MEK and MAPK.   
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 Activated MAPK can exhibit negative feedback at many stages of the 
RAS/MAPK pathway through phosphorylation.  It can phosphorylate several RTKs, 
downregulating their activation, as well as activating tyrosine phosphatases which 
dephosphorylate the RTK and inactivate it (Lake, Corrêa, & Müller, 2016).  Activated 
ERK2 can phosphorylate SOS1, which interferes with its binding to GRB2 and its 
association with the plasma membrane (Kamioka, Yasuda, Fujita, Aoki, & Matsuda, 
2010).  MAPK is also involved in a negative feedback loop involving RAF1.  P-MAPK 
phosphorylates RAF1, causing it to become hyperphosphorylated and desensitized, which 
prevents it from interacting with RAS (Dougherty et al., 2005).  Phosphorylation of 
BRAF by P-MAPK may interfere with BRAF’s dimerization with RAF1 as well as with 
its interaction with RAS (Lake et al., 2016).  Additionally, P-MAPK phosphorylates 
MEK1 which inhibits the kinase activity of MEK1, interferes with its binding with 
ERK2, and reduces the activity of MEK2 when dimerized with MEK1 (Lake et al., 
2016).  There is also evidence that P-MAPK acts on the scaffolding protein kinase 
suppressor of RAS (KSR).  KSR interacts with RAF, MEK, and MAPK and positively 
regulates signaling, which is disrupted when phosphorylated by P-MAPK  (Lake et al., 
2016).  Furthermore, inhibition of MEK and MAPK may result in sustained RAS 
activation due to inactivation of the RAS-GAP neurofibromin (Hennig et al., 2016).  This 
indicates that there is a negative feedback loop from MEK and MAPK that activates 
neurofibromin and subsequently downregulates RAS activation.   
 The RAS/MAPK also uses negative feedback loops from transcriptional products 
of MAPK.  Dual-specificity MAPK phosphatases (MKPs) dephosphorylate and inactivate 
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MAPK (Lake et al., 2016).  Transcription of MKPs can be induced by P-MAPK and can 
then act on P-MAPK in both the nucleus and cytoplasm (Caunt & Keyse, 2013).  
Transcription of sprouty proteins (SPRY1/2) are also induced by P-MAPK, which inhibit 
signaling by RAS (Lake et al., 2016). 
 When mutations in the RAS/MAPK pathway are introduced in tumor cells, the 
increased activation of the pathway is due to the tumor cells having unregulated growth, 
and does not have the same effect on non-tumor cell lines.  These negative feedback 
loops in the RAS/MAPK pathway may explain why there was not an increased amount of 
MAPK activation as was expected in the mutated rasopathy cells.  A high level of P-
MAPK would inhibit activation of the RAS/MAPK pathway, leading to decreasing levels 
of P-MAPK and higher levels of inactive MAPK, which the data in this thesis shows.   
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